Nonresponsiveness to Aspirin and Clopidogrel After Drug-Eluting Stent Placement

Dual nonresponsiveness to aspirin and clopidogrel was relatively rare but imparted a significant risk for DES thrombosis and adverse outcome.

Aspirin and clopidogrel commonly are prescribed together for patients who undergo coronary stenting. But, how many patients are resistant to one or both agents, and what does such resistance mean, clinically? In this reanalysis of a prospective study of patients who underwent drug-eluting stent (DES) placement, investigators determined platelet reactivity (as measured by light transmittance aggregometry to a variety of stimuli) in 746 patients who received dual antiplatelet therapy; reactivity was then linked to the rate of probable or definite DES thrombosis at 6 months.

The incidence of dual nonresponsiveness to aspirin and clopidogrel was 6%. The incidence of DES thrombosis was much higher in dual nonresponders (11.1%) than in those who r…

Reviewing Author

Kirsten E. Fleischmann, MD, MPH

Disclosures

Grant/Research SupportNational Institutes of Health

Leadership Positions in Professional SocietiesAmerican College of Cardiology/American Heart Association

Kirsten E. Fleischmann, MD, MPH

Disclosures

Grant/Research SupportNational Institutes of Health

Leadership Positions in Professional SocietiesAmerican College of Cardiology/American Heart Association